NICE are shortly going to be carrying out an appraisal to assess if they should approve Mepoluzimab for routine use in treating EGPA ( CSS ). it is very important that NICE should be given evidence of the patient experience of this drug, both good and bad. If you have had experience of being treated with Mepoluzimab and are prepared to share your experience please contact John Mills John.mills@vasculitis.org.uk
Extracts from these personal patient experiences maybe used in the vasculitis UK submission to the NICE appraisal committee
Thank you